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Abstract 
 
Objective: To determine whether brain volume is associated with functional outcome after acute ischemic stroke 
(AIS).  
Methods: We analyzed cross-sectional data of the multi-site, international hospital-based MRI-GENetics Interface 
Exploration (MRI-GENIE) study (July 1, 2014- March 16, 2019) with clinical brain magnetic resonance imaging 
(MRI) obtained on admission for index stroke and functional outcome assessment. Post-stroke outcome was 
determined using the modified Rankin Scale (mRS) score (0-6; 0: asymptomatic; 6 death) recorded between 60-190 
days after stroke. Demographics and other clinical variables including acute stroke severity (measured as National 
Institutes of Health Stroke Scale score), vascular risk factors, and etiologic stroke subtypes (Causative Classification 
of Stroke) were recorded during index admission.  
Results: Utilizing the data from 912 acute ischemic stroke (AIS) patients (65±15 years of age, 58% male, 57% 
history of smoking, and 65% hypertensive) in a generalized linear model, brain volume (per 155.1cm3) was 
associated with age (β -0.3 (per 14.4 years)), male sex (β 1.0) and prior stroke (β -0.2). In the multivariable outcome 
model, brain volume was an independent predictor of mRS (β -0.233), with reduced odds of worse long-term 
functional outcomes (OR: 0.8, 95% CI 0.7-0.9) in those with larger brain volumes. 
Conclusions: Larger brain volume quantified on clinical MRI of AIS patients at time of stroke purports a protective 
mechanism. The role of brain volume as a prognostic, protective biomarker has the potential to forge new areas of 
research and advance current knowledge of mechanisms of post-stroke recovery. 
 
Keywords: 1. acute ischemic stroke, 2. Brain volume, 3. Outcome, 4. MRI 
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Abbreviations 
 
CCS: causative classification system 
CE: major cardiac embolic 
LAA: large artery atherosclerosis  
mRS: modified Rankin Scale  
NIHSS: National Institutes of Health Stroke Scale score 
SAO: small artery occlusion 
SD: standard deviation  
IQR: interquartile range 
Vbrain: brain volume 
WMHv: white matter hyperintensity volume 
eR: effective reserve 
AIS: acute ischemic stroke 
MRI: magnetic resonance imaging 
DWIv: acute stroke lesion volume segmented on diffusion-weighted imaging  
AIC: Akaike Information Criterion 
BIC: Bayes Information Criterion  
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Introduction 
Stroke is a leading cause of death [1] and disability [2] in adults. However, while early and accurate modeling of 
outcome holds great promise, the contributing factors to delineate and predict stroke outcome are poorly understood 
[3]. Brain volume (Vbrain) has been studied in healthy and diseased populations [4–7], while brain reserve, the 
capacity of the brain to compensate for injury or disease, is often related to the maximum brain size in life, using 
intracranial volume as a surrogate measure [8]. Effective reserve (eR) assesses the remaining reserve after negative 
effects of insults and disease have been taken into account [9]. As such, eR is likely to relate to Vbrain at the time of 
scan. While Vbrain has been studied in relation to reserve in Alzheimer’s disease [7], studies relating it to outcome 
after acute ischemic stroke (AIS) are missing. 
 
Automated algorithms assess Vbrain using brain extraction and, if possible, tissue classification. However, algorithms 
are commonly designed for T1-weighted high-resolution images [10–12]. Recently, a translational methodology for 
clinical Fluid Attenuated Inversion Recovery (FLAIR) images, a common sequence in clinical assessment of AIS 
patients, has been developed [13]. 
  
Here, we posit Vbrain as a marker of brain health, which is influenced by the lifetime exposures to vascular risk 
factors. We hypothesized that larger Vbrain acts as a protective mechanism in AIS patients, leading to better post-
stroke functional outcomes. To investigate this hypothesis, we assessed automatically determined Vbrain in 912 AIS 
patients and its association with outcome measured by the modified Rankin Scale (mRS) score, 60 to 190 days after 
stroke. 
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Materials and Methods 
Standard protocol approvals, registrations, and patient consent 
At time of enrollment, informed written consent was obtained from all participating patients or their surrogates. The 
use of human patients in this study was approved by each site’s Institutional Review Board, in accordance with the 
1964 Helsinki declaration and its later amendments or comparable ethical standards. 
Study design, setting, and patient population 
This study was conducted between July 1, 2014 and March 16, 2019. The MRI-GENetic Interface Exploration 
(MRI-GENIE) study is a large-scale, international, hospital-based collaborative study of AIS patients [14].  Patients 
>18 years of age presenting to the Emergency Department of participating centers with signs and symptoms of AIS 
were approached for enrollment in the institutional stroke registries. Those with AIS confirmed on the brain MRI 
obtained within 48 hours of admission and blood samples available for genetic studies were eligible for inclusion in 
the MRI-GENIE study. Approval of the protocol was obtained from each site’s institutional review board or ethics 
committee. FLAIR images, a standard sequence of each hospital’s clinical AIS MRI protocol, were used for 
automated white matter hyperintensity volume (WMHv) extraction [13,15] in 2,528 patients from 12 sites (7 
European, 5 US based). Basic demographics and clinical phenotypes, such as age, sex, prior stroke, hypertensive 
and smoking (ever/never) status, as well as stroke subtypes derived using the Causative Classification of Stroke 
system [16] (undetermined, large artery atherosclerosis (LAA), major cardiac embolic (CE-major), small artery 
occlusion (SAO) and ‘other’) were recorded on the hospital admission. Each patient was evaluated by a neurologist 
on admission for acute stroke severity measured using the National Institutes of Health Stroke Scale (NIHSS) score 
(0-42; 0 asymptomatic, 42: severe stroke). Functional outcome assessed as mRS scores (0-6; 0: asymptomatic; 6: 
death) was recorded between 60-190 days after stroke [17]. These data were available for a subset of 912 patients 
from six of the sites in the study. Figure 1 describes the cohort selection and Table 1 summarizes the data used in 
this work. 
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Additionally, we developed a validation set of 142 AIS patients from the larger cohort by deriving manual brain 
segmentations (Table 1). We used the Vbrain calculated from the manual brain extraction for quantitative evaluation 
of the efficacy of the brain extraction algorithm. Furthermore, acute stroke lesion volumes were manually segmented 
on diffusion-weighted imaging (DWIv) in 37.3% (340/912) of patients (median 2.83cc; interquartile range: 0.81-
17.4cc), and utilized them to demonstrate that Vbrain estimates are independent of the acute stroke lesion size. 
Automated brain volume determination from FLAIR images 
We used a brain extraction method for clinical FLAIR scans based on a U-Net convolutional neural network 
architecture (Neuron-BE), implemented using the open-source library neuron (http://github.com/adalca/neuron 
[18]). Neuron-BE contains five downsampling and five upsampling levels. Initially, the image intensities are 
roughly normalized by scaling the 97th percentile of the image intensities to 1. Each up-/downsampling is achieved 
using 2x2 upsample/maxpool operations and each level contains two convolution layers with 128 features per layer. 
Network parameters are optimized using the Adadelta stochastic optimizer [19] with mini-batches of size 16. We 
augmented the data to mimic the observed conditions in clinical data for each batch through random intensity 
scaling (contrast factor between 0.7-1.3), random ghosting effects (at most 3 “copies” of the brain), as well as 
additive Gaussian and Perlin noise (standard deviations of 0.4 and 0.5, respectively). The network parameters were 
learned on a set of 69 patient scans for which we manually outlined the brain. After applying our convolutional 
neural network to a patient’s FLAIR image, we closed holes in the resulting segmentation mask, and identify the 
largest connected component as the brain mask [20]. These brain masks can be used to estimate total brain volume, 
i.e. ventricles, gray and white matter. Here, we applied the masks to the original scan and intensity normalized the 
resulting image using a mean-shift algorithm, setting the intensity of the normal appearing white matter to 0.75. 
From the resulting image voxel intensities below 0.375 were then excluded and Vbrain was calculated. A schematic of 
this process is shown in Figure 2. 
Statistical analysis and model description 
To assess the efficacy of Neuron-BE, we calculated the correlation between total brain volume estimates in the 
validation set of 142 patients with the manually extracted volumes (Pearson’s correlation coefficient). In addition, 
we calculated the overlap between manual and automated outlines (Dice coefficient) and confirmed that the 
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estimated brain volume, after intensity normalization and thresholding, is independent of the DWIv in the set of 340 
patients with manually extracted DWIv using Pearson’s correlation coefficient. 
 
Brain volume model. We then determined the collinearity between the phenotypes used in our study and assessed 
associations with Vbrain using a generalized linear model with backward elimination, iteratively removing non-
significant variables. The initial brain volume model is given by 
  𝑉"#$%&~	𝑎𝑔𝑒 + 𝑠𝑒𝑥 + log(𝑊𝑀𝐻𝑣) + 𝑝𝑟𝑖𝑜𝑟	𝑠𝑡𝑟𝑜𝑘𝑒 + ℎ𝑦𝑝𝑒𝑟𝑡𝑒𝑛𝑠𝑖𝑜𝑛 + 𝑠𝑚𝑜𝑘𝑖𝑛𝑔 +𝑁𝐼𝐻𝑆𝑆 + 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 + 𝐶𝐸 +𝑆𝐴𝑂 + 𝐿𝐴𝐴 + 𝑂𝑡ℎ𝑒𝑟, (Eq.1) 
  
including age, sex, WMHv, history of prior stroke, CCS stroke subtypes CE, SAO, LAA, and Other (yes/no), 
NIHSS, diabetes, hypertensive and smoking status. The CCS category ‘Undetermined’ was not included. Prior to 
model fit, WMHv were log transformed and continuous variables (age, WMHv, and brain volume) were 
standardized by subtracting the mean and dividing by their standard deviations.  
 
Outcome model. We used the determined relationships between observed phenotypes and the extracted brain 
volume determined in our brain volume model to guide the selection of interaction terms to be included in the 
outcome model, given by  
 𝑚𝑅𝑆	~	𝑎𝑔𝑒 + 𝑠𝑒𝑥 + log(𝑊𝑀𝐻𝑣)+ 𝑝𝑟𝑖𝑜𝑟	𝑠𝑡𝑟𝑜𝑘𝑒 + ℎ𝑦𝑝𝑒𝑟𝑡𝑒𝑛𝑠𝑖𝑜𝑛 + 𝑠𝑚𝑜𝑘𝑖𝑛𝑔 + 𝑁𝐼𝐻𝑆𝑆 + 𝑑𝑖𝑎𝑏𝑒𝑡𝑒𝑠 + 𝐶𝐸 +𝑆𝐴𝑂 + 𝐿𝐴𝐴 + 𝑂𝑡ℎ𝑒𝑟 +	𝑉"#$%& +	∑ 𝑖𝑛𝑡𝑒𝑟𝑎𝑐𝑡𝑖𝑜𝑛	𝑡𝑒𝑟𝑚𝑠. (Eq. 2) 
 
Parameters of the outcome model were estimated using ordinal regression and backward elimination was performed, 
iteratively removing non-significant parameters. We investigated the efficacy of this model by comparing it to a 
base model using a χ2 test, the Akaike Information Criterion (AIC) and the Bayes Information Criterion (BIC). The 
base model is defined as the outcome model after backward elimination without Vbrain. We furthermore included 
site, i.e. institution of acquisition, as a nuisance parameter in all models. 
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To validate our findings, we utilized 100 5-fold cross-validation, where the data were divided 100 times into five 
disjoint sets/folds of approximately equal size. The model fit was then repeated five times by leaving one of the 
folds out for each set of folds, which allowed us to assess the stability of our parameter estimates by calculating 
mean and standard deviation. All statistical analyses were conducted using the computing environment R [21]. 
Significance was set at P<.05. 
Data Availability Statement 
The authors agree to make the data, methods used in the analysis, and materials used to conduct the research 
available to any researcher for the express purpose of reproducing the results and with the explicit permission for 
data sharing by the local institutional review board.  
Results 
An overview of the cohort characteristics is found in Table 1. Of the 912 stroke patients with an average age 
(standard deviation, SD) of 65.3 (14.5) years, 58.3% were male, 65.2% were hypertensive, and 56.9% smoked. On 
average, patients had a median mRS score of 2 (inter-quartile range (IQR): 2; mRS of 0: 17%; mRS of 1: 37%; mRS 
of 2: 19%; mRS of 3: 13%; mRS of 4: 9%; mRS of 5: 1%), and an NIHSS score (mean (SD)) of 5.3 (5.5), while 
7.6% have had a prior stroke. Significant difference in patients with manual stroke lesion volume estimates were 
found for smoking (higher prevalence), mRS (better outcome), and SAO (lower prevalence) and Undetermined 
(higher prevalence) stroke subtypes, compared to those where manual stroke lesion estimates were not available. 
 
The Pearson’s correlation coefficient r and mean Dice coefficient d between manual and automated total brain 
volumes in the validation set were determined as r=0.94 and d=0.94±0.02. Additionally, the correlation between 
DWIv and Vbrain was not significant, whereas Vbrain was associated with age, sex, hypertension, WMHv, and 
smoking. Univariable analysis results are summarized in Table 2.  
 
Brain volume model. We reduced the full brain volume model (Eq. 1) through backward elimination (see Table 3). 
Finally, we obtained associations of Vbrain with age, sex, and prior stroke. The model estimation is summarized in 
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Table 2. Our results showed that male patients have larger Vbrain compared to female patients. Prior stroke, as well 
as an increase in age (per 14.4 years in the model) were associated with a decreased brain volume (per 155.1cc).  
 
Outcome model. The full outcome model (Eq. 2), with interaction terms between Vbrain and age, sex, and prior 
stroke, was then reduced using backward elimination (see Table 3). In the final step, we obtained associations of 
mRS with age, prior stroke, hypertension, NIHSS, LAA and Other stroke subtypes, as well as Vbrain. 
 
The parameters of the outcome and base models, i.e. the outcome model without Vbrain as a factor, are summarized in 
Table 2. Older individuals, those with history of prior stroke, HTN, those with LAA and Other stroke subtype, and 
with higher NIHSS Score on admission had worse outcome (higher mRS). The inverse was observed for Vbrain. 
Comparison of both models suggests that including Vbrain in the model explains the observed data better than the 
corresponding base model (AICbase=2714.9; AICoutcome=2703.8; BICbase=2796.8; BICoutcome=2790.4). 
 
Odds ratios (OR) and confidence intervals (CI) of both models (Figure 3) showed an increase in odds of worse 
outcome (higher mRS) for age (base OR: 1.41; outcome OR: 1.32), NIHSS (base OR: 1.19; outcome OR: 1.19), 
hypertension (base OR: 1.42; outcome OR: 1.38), prior stroke (base OR: 2.13; outcome OR: 2.00), and in case of an 
LAA (base OR: 1.37; outcome OR:1.37), and ‘other’ stroke subtype (base OR: 1.93; outcome OR: 1.84). In the 
outcome model, an increase in Vbrain showed a reduction in odds for worse outcome (OR: 0.79). Validating our 
results using cross-validation showed consistent trends with ORs of 1.24±0.04 for age, 2.27±0.29 for prior stroke, 
1.44±0.09 for hypertension, 1.35±0.10 for CCS-LAA, 1.66±0.17 for CCS-Other, 1.19±0.01 for NIHSS and 
0.79±0.02 for Vbrain. Odds-ratios for age and Vbrain reflect an increase by 14.4 years and 155.1cc, respectively, due to 
the standardization used in the model fit. 
Discussion 
In a large cohort of AIS patients, we demonstrated that Vbrain is an important factor of post-stroke outcome. We 
derived the Vbrain estimates automatically on clinical FLAIR MRI sequences using a novel, deep-learning algorithm, 
and confirmed good agreement of the automated total brain volumes with manually extracted “gold standard” 
estimates. Furthermore, we verified independence of Vbrain estimates from measurement of acute infarct volume 
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(further strengthened by lack of association between Vbrain and NIHSS) and demonstrated that a larger Vbrain acts as a 
protective factor in functional outcome after stroke. 
 
Utilizing the extracted Vbrain as an independent variable in the outcome model of acute stroke, we demonstrated that 
age, history of prior stroke and Vbrain are important markers of functional post-stroke outcome. Both age and history 
of prior stroke have been reported previously; however, the link between Vbrain and mRS is novel. Moreover, these 
findings are significant, as they bridge a long-standing conceptual divide between the burden of pre-existing brain 
pathology and its impact on susceptibility of the brain to acute insult such as stroke. Larger brain volumes have been 
associated with the notion of higher brain reserve, in which intracranial volume is used as a measure of maximum 
brain volume over the life span [9,22]. However, the brain volume calculated here does not reflect each patient’s 
maximum brain volume, but the current volume which may have been altered due to disease or normal brain aging. 
Brain volume at the time of MRI scan directly relates to the recently proposed concept of effective reserve (eR), 
which quantifies how the remaining brain reserve compensates for new diseases or insults [9]. This is further 
reflected in the protective nature of larger brain volumes, which were associated with better outcome in our study, 
and may represent a sign of eR in AIS populations.  
 
Brain volume, however, is modified by common stroke risk factors, as shown in the brain volume model. Using 
backward elimination, our analysis of brain volume determinants reproduced known associations in healthy 
populations, where increasing age leads to a reduced brain volume due to general brain atrophy [8] and males having 
larger brain volumes compared to women, likely due to anthropometric differences between sexes [23]. 
Additionally, we show a reduction in Vbrain depending on history of prior stroke, which may indicate increased 
atrophy after incidence of stroke, independent of aging. Furthermore, we observed a negative trend of Vbrain with 
hypertension. Although this analysis did not reach statistical significance (p<0.1), associations of hypertension with 
brain volume have been previously reported [24]. We were not able to identify an effect of WMHv on Vbrain in our 
study. Many of the presented associations are thought to cause increased WMHv; however, the increase of WMHv 
may be independent from alterations in Vbrain. Future studies will aim to investigate whether WMHv may be 
associated with local alterations to the specific brain compartments, such as periventricular areas.  
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This study has several limitations. It should be emphasized that this is not a direct study of brain atrophy, as 
intracranial volume or serial imaging was not available for this cohort. Instead, this study focuses on the brain 
volume, which may act as a more direct measure of eR, or a cross-sectional metric of “lifetime brain health,” 
assessed at the time of stroke. Other factors can influence the estimation of brain volume in this study, such as brain 
swelling, utilization of FLAIR imaging instead of commonly used T1 sequence, as well as the clinical resolution of 
the investigated data. However, the comparison of the Vbrain estimates of the presented method to manually 
determined brain volumes showed good agreement, while including site as a nuisance factor in all models, and no 
associations were found between acute lesion size and total brain volume. In addition, the time of day at acquisition 
has been shown to influence brain volume with larger brain volumes earlier in the day. However, Nakamura et al. 
[25] estimated the error on brain volume estimation to be below 0.2% at a resolution of 1x1x3mm3, in our cohort 
corresponding to 2-4cc of brain volume, and subsequently much smaller than the increment of 155.1cc described in 
our analysis. Additionally, our outcome model did not take acute stroke lesion volume, its location, or other chronic 
discrete infarction beyond WMHv into account, because only a small subset (n=340; 37%) of our patients had DWIv 
available for analysis. However, we utilized the NIHSS score as a measure of stroke severity, and given its 
collinearity with DWIv, we do not expect any significant changes in the model with respect to its effect on Vbrain. 
Similarly, there was no interaction between CCS stroke subtype and Vbrain. Furthermore, with regard to stroke 
location, it is unlikely that the location, independent of lesion size, will affect the estimates of Vbrain. To identify 
chronic lesions, we utilized a fully automated segmentation pipeline specifically developed for clinical FLAIR 
sequences, while excluding hyperintensities not being classified as leukariosis. While smaller, predominantly 
subcortical strokes could have been missed or perhaps erroneously included as part of the WMHv in case of small 
chronic lacunar infarctions, to date not dedicated pipeline for identifying chronic, discrete infarctions in mono-
modal, clinical data, other than leukariosis, exist. Future developments of such pipelines may further help to identify 
additional associations between Vbrain and chronic lesion burden. 
 
The goal of our study was to assess whether antecedent brain volume is an independent factor that can be utilized in 
stroke outcome models and we have demonstrated its independence with respect to the acute lesion volume and 
etiologic stroke subtype. Additionally, other factors, such as stroke treatment can influence the overall outcome of a 
patient. While we had no information on acute interventions in this cohort, the treatment itself is not likely to 
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systematically influence brain volume or to have major effects in the acute stages of the stroke (<48 hours) in which 
Vbrain was assessed. 
 
In this work, we present a simple, but important, additional biomarker for assessment of functional post-stroke 
outcome. The proposed brain extraction methodology can provide consistent, precise and reliable estimates of brain 
volume on clinical brain MRI scans without time intensive manual labor. Using cross-validation and large-scale, 
international, multi-site data, we demonstrate that our results are generalizable and are directly applicable to clinical 
grade data, making brain volume a complementary marker for state-of-the-art stroke outcome assessment in the 
clinic.  
Conclusion 
We established brain volume as an important, but often overlooked, biomarker associated with AIS outcome. We 
showed that brain volume is associated with age, sex and history of prior stroke and demonstrated that it has an 
independent, protective effect, where a larger brain volume relates to better outcome. Importantly, the assessment of 
brain volume on clinical MR images offers an opportunity for immediate translation and opens up new areas of 
research to help advance current knowledge of risks and outcomes in AIS populations.  
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Figure 1: Cohort selection. Of the patients with automated WMHv estimates, 142 underwent manual brain 
extraction (validation set). A subset of 912 patients was used for analysis in this study, of which 340 had manually 
determined acute lesion volume (DWIv), which form the DWIv set. Abbreviations: DWIv - diffusion weighted 
imaging acute lesion volume, mRS - modified Rankin Scale score, WMHv - white matter hyperintensity volume, 
HTN - hypertension, DM2 - type 2 diabetes. 
 
 
 
Figure 2: Pipeline schematic to extract brain volume. After brain extraction utilizing Neuron-BE, image 
intensities were normalized and then thresholded to determine a final brain mask (yellow outline) from which brain 
volume was calculated. 
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Figure 3: Odds ratios estimated for base (blue) and final (red) model of outcome (mRS score 0-6). In both 
models, age and history of stroke increase the odds of a higher mRS score, reflecting worse outcome. Larger brain 
volumes reduce the odds of a higher mRS score, reflecting better outcome. The odds ratios for age and Vbrain reflect 
an increase by 14.4 years and 155.1cm3, respectively, due to the standardization used in the model fit. 
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Table 1: Study cohort characterization. Smoking was assessed as ever/never, based on past or current history of 
smoking. Abbreviations: CCS: causative classification system; CE major: major cardiac embolic; LAA: large artery 
atherosclerosis; mRS: modified Rankin Scale; NIHSS: National Institutes of Health Stroke Scale score; SAO: small 
artery occlusion; sd: standard deviation; IQR: interquartile range; Vbrain: brain volume; WMHv: white matter 
hyperintensity volume. 
 Overall Validation set DWIv set 
n 912 142 340 
Age, years (mean (sd)) 65.3 (14.5) 62.1 (16.9) 66.52 (14.1) 
Male sex, n (%) 532 (58.3) 86 (59.7) 202 (59.4) 
Smoking, n (%; n missing) 519 (56.9) 75 (53.6; 4) 212 (62.4) 
Hypertension, n (%; n missing) 595 (65.2) 91 (64.5; 3) 207 (60.9) 
Prior stroke, n (%; n missing) 70 (7.6) 25 (18.2; 1) 20 (5.9) 
mRS score (median (IQR); n missing) 2 (2) 1 (2; 99) 1 (1) 
NIHSS score (mean (sd); n missing) 5.3 (5.5) 4.8 (4.9; 84) 5.3 (5.5) 
WMHv, cm3; mean (sd) 11.0 (12.9) 14.2 (16.7) 10.7 (13.0) 
Vbrain, cm3; mean (sd) 1403.1 (155.1) 1273.7 (164.5) 1392.9 (154.9) 
CCS subtype    
Undetermined, n (%) 349 (38.3) 61 (42.4) 149 (43.8) 
CE Major, n (%) 162 (17.8) 23 (16.0) 58 (17.1) 
LAA, n (%) 194 (21.3) 30 (20.8) 71 (20.9) 
SAO, n (%) 149 (16.3) 20 (13.9) 39 (11.5) 
Other, n (%) 58 (6.4) 10 (6.9) 23 (6.9) 
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Table 2: Parameter estimates for all models. 95% confidence intervals are reported in parentheses. Abbreviations: 
HTN: hypertension; CE major: major cardioembolic; Eq: equation; LAA: large artery atherosclerosis; mRS: 
modified Rankin Scale; NIHSS: National Institutes of Health Stroke Scale score; SAO: small artery occlusion; 
Vbrain: brain volume; WMHv: white matter hyperintensity volume 
Model 
Brain volume (Linear regression) Outcome (mRS; Ordinal regression) 
Univariable Multivariable (Eq. 3) Univariable 
Multivariable 
 (Eq. 5) 
Base 
(Eq. 6) 
Estimate P Estimate P  Estimate P Estimate P Estimate P 
Age -0.33 (-0.39--0.26) <.001 
-0.30 
(-0.36--0.25) <.001 
0.33 
(0.21-0.45) <.001 
0.28 
(0.13-0.42) <.001 
0.34 
(0.20-0.48) <.001 
Sex (Male) -0.60 (-0.69--0.52) .03 
1.00 
(0.89-1.11) <.001 
-0.51 
(-0.75--0.27) <.001 - - - - 
Prior stroke 0.03 (-0.04-0.10) .11 
-0.21 
(-0.41-0.00) .04 
1.12 
(0.69-1.54) <.001 
0.70 
(0.23-1.16) .001 
0.76 
(0.30-1.21) .003 
HTN 0.23 (0.12-0.33) .04 - - 
0.51 
(0.26-0.76) <.001 
0.32 
(0.06-0.58) .008 
0.35 
(0.09-0.62) .01 
NIHSS -0.00 (-0.01-0.00) .31 - - 
0.17 
(0.15-0.19) <.001 
0.18 
(0.15-0.20) <.001 
0.18 
(0.15-0.20) <.001 
LAA 0.01 (-0.06-0.09) .07 - - 
0.59 
(0.30-0.88) <.001 
0.31 
(0.01-0.61) .03 
0.32 
(0.02-0.61) .04 
Other -0.02 (-0.09-0.04) .13 - - 
-0.19 
(-0.65-0.27) .41 
0.61 
(0.10-1.11) .01 
0.61 
(0.10-1.11) .01 
SAO 0.01 (0-0.06-0.08) .08 - - 
-0.05 
(-0.35-0.25) .75 - - - - 
CE 0.04 (-0.03-0.11) .07 - - 
0.37 
(0.05-0.69) .02 - - - - 
WMHv -0.09 (-0.15--0.02) .009 - - 
0.04 
(-0.08-0.16) .49 - - - - 
Smoking -0.08 (-0.18-0.02) .04 - - 
-0.07 
(-0.31-0.16) .55 - - - - 
Diabetes 0.03 (-0.04-0.10) .07 - - 
0.63 
(0.35-0.91) <.001 - - - - 
Vbrain - - - - -0.34 (-0.46--0.22) <.001 
-0.23 
(-0.36--0.11) <.001 - - 
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Table 3: Summary of backward elimination steps. Phenotypic variables removed during each iterative step, 
including the corresponding p-values in parentheses, for both base and outcome models. Interaction terms are 
represented by ‘:’. 
 
 Iteration 
Model 1 2 3 4 5 6 7 8 9 
Base SAO 
(.80) 
Other 
(.63) 
CE 
(.63) 
NIHSS 
(.50) 
WMHv 
(.40) 
LAA 
(.41) 
Diabetes 
(.34) 
Smoking 
(.24) 
Hypertension 
(.08) 
Outcome CE 
(.96) 
WMHv 
(.92) 
Sex:Vbrain 
(.78) 
Prior 
stroke:Vbrain 
(.71) 
Smoking 
(.44) 
SAO 
(.30) 
Age:Vbrain 
(.08) 
Sex 
(.07) 
- 
 
